Evidence map›Paper›PMID 36060253›Full record

ArticleFrontiers in molecular biosciences2022

PRR11 promotes cell proliferation by regulating PTTG1 through interacting with E2F1 transcription factor in pan-cancer.

Haibo Zhang, Ziqing He, Li Qiu, Jinfen Wei, Xiaocheng Gong, Mingjian Xian, Zixi Chen, Ying Cui, Shuying Fu, Zihao Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Haibo ZhangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Ziqing HeSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Li QiuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Jinfen WeiSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Xiaocheng GongSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Mingjian XianCollege of Animal Science, South China Agricultural University, Guangzhou, China.
Zixi ChenSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Ying CuiSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Shuying FuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Zihao ZhangCollege of Animal Science, South China Agricultural University, Guangzhou, China.
Bowen HuCollege of Animal Science, South China Agricultural University, Guangzhou, China.
Xiquan ZhangCollege of Animal Science, South China Agricultural University, Guangzhou, China.
Shudai LinSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Hongli DuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The upregulated proline rich 11 (PRR11) plays a critical role in cancer progression. The relevant biological functions of PRR11 in pan-cancer development are not well understood. In the current study, we found that

Indexed as

cell cyclecell migrationpan-cancerpituitary tumor-transforming gene 1 (PTTG1)proline rich 11 (PRR11)

Identifiers

PMID36060253
PMCPMC9437250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.